InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,969.95
(
0.69%
)
US TECH 100
20,517.20
(
1.45%
)
Dow Jones
43,775.38
(
0.10%
)
Brent Oil
75.38
(
0.41%
)
Bitcoin
76,251.96
(
0.80%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

SpleniusCapitis

Send PM Follow Ignore
Followers 0
Posts 24
Boards Moderated 0
Alias Born 08/30/2011

SpleniusCapitis

Re: rocky301 post# 44672

Tuesday, 06/05/2012 5:56:12 PM

Tuesday, June 05, 2012 5:56:12 PM

Post# of 92948
rocky301,

I took notes from their last shareholder's meeting and they were talking about not needing immunosuppressants when they were talking about their hemangioblast program.

What trials have they used immunosuppressants for, and was it simply as a precautionary method?
Under the findings of their report for dryAMD and wetSMD at:

http://www.ncbi.nlm.nih.gov/pubmed/22281388?dopt=Abstract

it says that "We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up